Literature DB >> 1378032

Circulating tumor-associated antigens detected by monoclonal antibodies against the polypeptide core of mucin--comparison of antigen MUSE11 with CA15-3.

Y Hinoda1, H Kakiuchi, N Nakagawa, Y Ohe, T Sugiyama, M Tsujisaki, K Imai, A Yachi.   

Abstract

The antigen MUSE11 detected by a monoclonal antibody (MAb) is an adenocarcinoma-associated antigen, while CA15-3 is a representative breast cancer-associated antigen detected by MAbs 115D8 and DF3. MAb MUSE11 showed higher binding activity to a synthetic peptide corresponding to the tandem repeat motif of the mucin core protein than that of MAb DF3, although MAb DF3 also had a significant binding activity indicating that MAbs MUSE11 and DF3 could recognize an identical polypeptide core. The reactivity of MAb DF3 to a breast cancer cell line MRK-neu-1 was completely abolished by neuraminidase treatment whereas that of MAb MUSE11 was partly conserved. The simultaneous measurement of the antigens MUSE11 and CA15-3 in sera from 35 cancer patients demonstrated that the incidence of abnormal serum level of CA15-3 was lower than that of antigen MUSE11. These data suggest that at least a part of the structural basis for the difference between the serum levels of antigen MUSE11 and CA15-3 could be carbohydrate side chains including sialic acids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378032     DOI: 10.1007/bf02777759

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  18 in total

Review 1.  The chemistry and mechanism of antibody binding to protein antigens.

Authors:  E D Getzoff; J A Tainer; R A Lerner; H M Geysen
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

2.  A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue.

Authors:  M Hareuveni; I Tsarfaty; J Zaretsky; P Kotkes; J Horev; S Zrihan; M Weiss; S Green; R Lathe; I Keydar
Journal:  Eur J Biochem       Date:  1990-05-20

3.  A sandwich enzyme immunoassay of an adenocarcinoma-associated antigen, YH206, in cancer sera.

Authors:  Y Hinoda; K Imai; T Ban; T Endo; A Yachi
Journal:  Jpn J Cancer Res       Date:  1987-06

4.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.

Authors:  A Girling; J Bartkova; J Burchell; S Gendler; C Gillett; J Taylor-Papadimitriou
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

5.  A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.

Authors:  J Burchell; J Taylor-Papadimitriou; M Boshell; S Gendler; T Duhig
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

6.  Structural analysis of the DF3 human breast carcinoma-associated protein.

Authors:  M Abe; D Kufe
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

7.  Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas.

Authors:  G R Merlo; J Siddiqui; C S Cropp; D S Liscia; R Lidereau; R Callahan; D W Kufe
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

8.  Immunochemical characterization of adenocarcinoma-associated antigen YH206.

Authors:  Y Hinoda; K Imai; T Ban; T Endo; A Yachi
Journal:  Int J Cancer       Date:  1988-11-15       Impact factor: 7.396

9.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.

Authors:  D F Hayes; H Sekine; T Ohno; M Abe; K Keefe; D W Kufe
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

10.  MAM-6 antigen, a new serum marker for breast cancer monitoring.

Authors:  J Hilkens; V Kroezen; J M Bonfrer; M De Jong-Bakker; P F Bruning
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

View more
  1 in total

1.  CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.

Authors:  P L Devine; M A Duroux; R J Quin; M A McGuckin; G J Joy; B G Ward; C W Pollard
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.